ABSTRACT
Venous thromboembolism is the major cause of death and important health problem. Anticoagulants is the mainstay modality of VTE treatment and rivaroxaban was the first novel anticoagulant approved for VTE treatment and secondary prevention in Russia. Current study was designed to assess efficacy and safety of rivaroxaban from the first day of VTE treatment. There were 78 patients in control group treated with LMWH and VKA, and 46 patients in the rivaroxaban group. Treatment duration was not less than 3 months. After 3 months there were 3 (3.85%) patients in control group and 1 (2.2%) patient in the rivaroxaban group with thrombus deterioration. Bleeding complications were observed in 6 (7.7%) patients in LMWH/VKA group and in 2 (4.3%) patients in the rivaroxaban group. CONCLUSION: results of the study show favorable benefit profile of rivaroxaban in VTE patients and rivaroxaban could be considered as initial therapy.
